Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2163843 | Translational Oncology | 2013 | 10 Pages |
Abstract
Multiple myeloma (MM) is preceded by monoclonal gammopathy of undetermined significance (MGUS). Up to date, it is difficult to predict an individual's time to disease progression and the treatment response. To examine whether the nuclear telomeric architecture will unravel some of these questions, we carried out. Three-dimensional (3D) telomere analysis on samples from patients diagnosed with MGUS and MM, as well as from patients who went into relapse. Telomere signal intensity, number of telomere aggregates, nuclear volume, and the overall nuclear telomere distribution (a/c ratio) were analyzed. The telomeric profiles allowed for the differentiation of the disease stages. The telomeric profiles of myeloma cells obtained from blood and bone marrow aspirates were identical. Based on this study, we discuss the use of 3D telomere profiling as a potential future tool for risk stratification and personalized treatment decisions.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ludger Klewes, Rhea Vallente, Eric Dupas, Carolin Brand, Dietrich Grün, Amanda Guffei, Chirawadee Sathitruangsak, Julius A. Awe, Alexandra Kuzyk, Daniel Lichtensztejn, Pille Tammur, Tiiu Ilus, Anu Tamm, Mari Punab, Morel Rubinger, Adebayo Olujohungbe,